Lumos Pharma Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lumos Pharma in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Lumos Pharma stock.
View analyst ratings for Lumos Pharma or view top-rated stocks.

Wall Street analysts have given Lumos Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Lumos Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Lumos Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Lumos Pharma.

Lumos Pharma will be holding an earnings conference call on Tuesday, March 9th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Lumos Pharma, Inc. (NASDAQ:LUMO) announced its quarterly earnings data on Tuesday, November, 10th. The company reported $0.21 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.65) by $0.86. The firm earned $0.07 million during the quarter, compared to analyst estimates of $7.80 million. Lumos Pharma had a negative trailing twelve-month return on equity of 10.58% and a negative net margin of 2,053.30%.
View Lumos Pharma's earnings history.

5 equities research analysts have issued twelve-month price objectives for Lumos Pharma's shares. Their forecasts range from $12.00 to $51.00. On average, they anticipate Lumos Pharma's stock price to reach $31.00 in the next year. This suggests a possible upside of 130.7% from the stock's current price.
View analysts' price targets for Lumos Pharma or view top-rated stocks among Wall Street analysts.

Some companies that are related to Lumos Pharma include Avadel Pharmaceuticals (AVDL), Homology Medicines (FIXX), 89bio (ETNB), Spero Therapeutics (SPRO), Kala Pharmaceuticals (KALA), Aldeyra Therapeutics (ALDX), Orphazyme A/S (ORPH), Puma Biotechnology (PBYI), Spruce Biosciences (SPRB), Mirum Pharmaceuticals (MIRM), Athenex (ATNX), DURECT (DRRX), Evolus (EOLS), Selecta Biosciences (SELB) and Fulcrum Therapeutics (FULC).
View all of LUMO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lumos Pharma investors own include Advanced Micro Devices (AMD), (NCLH), Northern Oil and Gas (NOG), Agilent Technologies (A), Air Lease (AL), Ampio Pharmaceuticals (AMPE), Bionano Genomics (BNGO), Chimerix (CMRX), Compagnie de Saint-Gobain (CODYY) and CorMedix (CRMD).

Lumos Pharma trades on the NASDAQ under the ticker symbol "LUMO."

Lumos Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (3.72%), Opaleye Management Inc. (3.39%), Wells Fargo & Company MN (1.42%), ExodusPoint Capital Management LP (0.45%), Investors Financial Group LLC (0.22%) and Bank of New York Mellon Corp (0.21%).
View institutional ownership trends for Lumos Pharma.

LUMO stock was sold by a variety of institutional investors in the last quarter, including Investors Financial Group LLC.
View insider buying and selling activity for Lumos Pharma or view top insider-selling stocks.

LUMO stock was bought by a variety of institutional investors in the last quarter, including Opaleye Management Inc., ExodusPoint Capital Management LP, Bank of New York Mellon Corp, Verition Fund Management LLC, Northern Trust Corp, Foster Group Inc., One68 Global Capital LLC, and Renaissance Technologies LLC.
View insider buying and selling activity for Lumos Pharma or or view top insider-buying stocks.

Shares of LUMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LUMO stock can currently be purchased for approximately $13.44.

Lumos Pharma has a market capitalization of $111.51 million and generates $940,000.00 in revenue each year. The company earns $-42,990,000.00 in net income (profit) each year or ($9.27) on an earnings per share basis.

Lumos Pharma employs 28 workers across the globe.

The official website for Lumos Pharma is www.lumos-pharma.com.

Lumos Pharma is headquartered at 4200 MARATHON BLVD. SUITE 200, AUSTIN TX, 78756.

Lumos Pharma's mailing address is 4200 MARATHON BLVD. SUITE 200, AUSTIN TX, 78756. The company can be reached via phone at 512-215-2630 or via email at [email protected]